Bio-Techne Navigates Mixed Market Signals in Q2, Sees Strength in Pharma and APAC
Bio-Techne's Q2 FY2026 results show flat organic revenue, as robust demand from large pharmaceutical clients countered persistent softness in the biotech and academic sectors. Management highlights strategic growth areas and expects gradual market improvement.